For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

You are here

Publications

Found 9 results
Author Title [ Type(Desc)] Year
Filters: Author is Murray, Henry W  [Clear All Filters]
Journal Article
Murray HW, Flanders KC, Donaldson DD, Sypek JP, Gotwals PJ, Liu J, Ma X.  2005.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.. Infect Immun. 73(7):3903-11.
Murray HW, Moreira AL, Lu CM, DeVecchio JL, Matsuhashi M, Ma X, Heinzel FP.  2003.  Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.. J Infect Dis. 188(3):458-64.
Murray HW, Luster AD, Zheng H, Ma X.  2017.  Gamma Interferon-Regulated Chemokines in Leishmania donovani Infection in the Liver.. Infect Immun. 85(1)
Murray HW, Mitchell-Flack M, Zheng H, Ma X.  2015.  Granzyme-mediated regulation of host defense in the liver in experimental Leishmania donovani infection.. Infect Immun. 83(2):702-12.
Murray HW, Mitchell-Flack M, Taylor GA, Ma X.  2015.  IFN-γ-induced macrophage antileishmanial mechanisms in mice: A role for immunity-related GTPases, Irgm1 and Irgm3, in Leishmania donovani infection in the liver.. Exp Parasitol. 157:103-9.
Murray HW, Zhang Y, Zhang Y, Raman VS, Reed SG, Ma X.  2013.  Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver.. Infect Immun. 81(7):2318-26.
Murray HW, Xiang Z, Ma X.  2006.  Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase.. Am J Trop Med Hyg. 74(6):1013-5.
Murray HW, Tsai CW, Liu J, Ma X.  2006.  Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18.. Infect Immun. 74(7):4370-4.
Murray HW, Tsai CW, Liu J, Ma X.  2006.  Visceral Leishmania donovani infection in interleukin-13-/- mice.. Infect Immun. 74(4):2487-90.